reports
- Hybridan Team
Hybridan Small Cap Feast: 2 February 2026
2nd February 2026 @HybridanLLP Our daily digest of news from UK Small Caps * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the Day Admissions: Last Friday 30th Jan, R...
Johnson & Johnson: 1 director
A director at Johnson & Johnson sold 100,000 shares at 221.229USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight We had been near-term bullish on the S&P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral. The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here. With that said, our intermediate-term outlook remains bullish (as of our 5/14/25 Co...
- Hybridan Team
- Jon Levinson
Hybridan Research: RUA Life Sciences: Journey to a Higher Value
The new accounting date is to September 2025, changed from March, so the next full audited report is for 18 months to be announced in January 2026. The trading-update on 4 November last week included a 12-month contribution from ABISS which was acquired on 9 September 2024. RUA stated its growth strategy is to increase the scale of the medical device and component manufacturing, reduce customer concentration, develop royalties from Biomaterials, and break-even. RUA Life Sciences operates in the...
- Hybridan Team
- Jon Levinson
Hybridan Small Cap Feast: 04 November 2025
4th November 2025 @HybridanLLP Our daily digest of news from UK Small Caps * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the Day Admissions: Shawbrook Group (SHAW....
Moody's Ratings says J&J's Ortho separation will modestly reduce scale...
Moody's Ratings (Moody's) said that on 14 October, Johnson & Johnson ("J&J") announced that it intends to separate its Orthopaedics business into an independent company called DePuy Synthes. The separation of the Orthopaedics business, which is part of J&J's medical devices segment ("MedTech") will ...
- Hybridan Team
- Jon Levinson
Hybridan Small Cap Feast: 25/06/2025
Our daily digest of news from UK Small Caps 25th June 2025 @HybridanLLP * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and Closing Price on prior day to Publication. Dish of the day Admissions: None Delistings: None today…....yesterday Urban Logistics Reit (SHED.L) left the Mai...
- Hybridan Team
- Jon Levinson
Hybridan Research: Sector Piece: Undervalued, Under Researched Small C...
Welcome to the first in a new series of thematic reports We will be focusing on undervalued and under researched small caps across a range of sectors, reflecting the challenges and general market apathy. We start with a general small cap growth theme. Further editions may focus on other sectors, in the pipeline, potentially, recruitment, and engineering. Last year we tackled AI, which is becoming ubiquitous, as well as cyber security. Both sectors could feature in future editions. The thesis...
- Hybridan Team
- Jon Levinson
Hybridan Monthly 1 May 2025
Hybridan Monthly, 1 May 2025 Market Comment: A contrarian view to companies delisting from the market The flurry of companies delisting from the market has accelerated since early 2024. The London Stock Exchange (“LSE”) has been an easy target for those eager to point the blame. Unfortunately, criticism towards the LSE is now synonymous with the media coverage of a company leaving the market. “The London Stock Exchange is on course for its worst year for departures since the financial crisis….” ...
- Hybridan Team
Hybridan Small Cap Feast: 24/04/2025
Our daily digest of news from UK Small Caps 24th April 2025 @HybridanLLP * A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Dish of the day Admissions: None Delistings: None What’s baking in the oven? Potential** Initial Public Offerings: 18th March: Uranium Energy Exploration,...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Johnson & Johnson and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 2 April 2025 in which we reassessed the appropriateness of the ratings in the context of ...
Moody's Ratings says J&J's talc overhang remains after court ruling, b...
Moody's Ratings (Moody's) said that Johnson & Johnson's ("J&J") talc overhang remains after its latest talc subsidiary bankruptcy attempt was denied in courts, but its strong business profile and financial flexibility mitigate ongoing litigation pressures. There is no change at this time to J&J's ra...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Near-Term Downside Likely Following False Breakouts Our long-term outlook remains bullish as long as the S&P 500 remains above 5770-5850 and 5600-5670 (worst case), and we are buyers at these levels. With that said, we see potential for near-term downside as the S&P 500, Nasdaq 100 (QQQ), and FANG+ (FNGS) (1) could not decisively break out to new highs, (2) display bearish false breakouts, (3) have fallen back into their 2+ month trading ranges, (4) are violating their 1+ month uptrends, and (5...
LLY ELI LILLY AND COMPANY
CFSL COCA-COLA FEMSA SAB DE CV (ADR)
JNJ JOHNSON & JOHNSON
BMY BRISTOL-MYERS SQUIBB COMPANY
AKOB EMBOTELLADORA ANDINA S.A. SERIES B ADS
FMX FOMENTO ECONOMICO MEXICANO S.A.B. DE C.V. ADS
BMTA BRITISH AMERICAN TOBACCO PLC ADS
PM PHILIP MORRIS INTERNATIONAL INC.
ABBV ABBVIE INC.
CCHGY COCA-COLA HBC AG
ABT ABBOTT LABORATORIES
AZN ASTRAZENECA PLC ADS
GSK. GLAXOSMITHKLINE PLC CEDEAR
IMBBY IMPERIAL BRANDS PLC
Moody's Ratings assigns Aaa ratings to Johnson & Johnson's sr. notes; ...
Moody's Ratings (Moody's) assigned Aaa ratings to the new senior unsecured note offerings of Johnson & Johnson ("J&J"). There are no changes to J&J's existing ratings including the Aaa senior unsecured long-term rating or the Prime-1 short-term rating. The outlook remains unchanged at stable. Proc...
- Hybridan Team
Hybridan Monthly, 3 February 2025
2025: The year of the Phoenix, NOT the Unicorn The pursuit of Unicorn companies valued at $1bn+ will always be newsworthy and exciting. VCs, Private Equity, Governments and Global Stock Exchanges will continue to fight and clamber over one another for the chance of courting them. Our collective attention should therefore not be where support is needed least. Our attention needs to be diverted back to the exciting and unloved. The majestic Phoenix company; known for its ability to be reborn f...
- Hybridan Team
- Jon Levinson
Hybridan Small Cap Feast: 03/02/2025
* A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication Dish of the day Admissions: On Friday 31st January, Cardiogeni (AQSE: CGNI) announced its IPO onto AQSE. The Group’s platform technology is developing a new class of life-saving cellular...
- Hybridan Team
- Jon Levinson
Hybridan Small Cap Feast: 29/01/2025
Banquet Buffet**** Angle 15.25p £42.75m (AGL.L) The innovative liquid biopsy Company with circulating tumour cell (CTC) solutions for research, drug development and clinical oncology reports successful trial results. Its dual circulating tumour DNA (ctDNA) and CTC-DNA workflow used, for the first time, an end-to-end Illumina solution for analysis. In the study, CTCs were isolated and harvested using the Parsortix system from a single blood tube taken from 27 lung cancer patients. CTCs and ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.